In this context, the PARP7 inhibitor RBN-2397, initially tested as a single agent in solid tumors with inconclusive results (clinical trial ID NCT04053673; https://clinicaltrials.gov/study/NCT04053673), is currently being evaluated in individuals with NSCLC who initially responded to treatment with a PD-1 or PD-L1 inhibitor but later experienced disease progression (clinical trial ID NCT05127590; https://clinicaltrials.gov/study/NCT05127590). This evidence concerns the gene CD274 and non-small cell lung carcinoma.